Biotest AG Signs Strategic Agreement for Yimmugo® Distribution in the U.S.

On October 2, 2024, Biotest AG announced the finalization of a long-term agreement with Kedrion Biopharma Inc. to distribute its immunoglobulin Yimmugo® in the United States. This follows the binding terms agreed upon in July.

The agreement is set to generate over $1 billion in revenue for Biotest over a seven-year period. The production of Yimmugo® commenced immediately following the approval of the Biologic License Application and preparations for its U.S. market launch in 2025 are in full swing.

Entering the U.S. market, which accounts for over 100 tons of IVIG sales annually worth $10 billion, marks a significant milestone for Biotest. Yimmugo® is set to penetrate this vital plasma derivatives sector.